<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151435">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994889</url>
  </required_header>
  <id_info>
    <org_study_id>B3461028</org_study_id>
    <nct_id>NCT01994889</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy</brief_title>
  <acronym>ATTR-ACT</acronym>
  <official_title>A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy, safety, and tolerability of an oral dose of 20 mg
      or 80 mg tafamidis meglumine soft gel capsules in comparison to placebo and given once
      daily, in addition to standard of care, for 30 months in subjects diagnosed with
      transthyretin cardiomyopathy (familial and wild-type).  The study is designed to assess the
      potential for benefit from treatment with tafamidis relative to placebo based on all-cause
      mortality and frequency of cardiovascular-related hospitalizations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality and frequency of cardiovascular-related hospitalization</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A hierarchical combination of the endpoints for a pooled analysis of the tafamidis treatment groups in comparison to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test (6MWT).</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline to Month 30 in the total distance walked in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline to Month 30 in the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular-related mortality</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The total number of deaths adjudicated as being related to cardiovascular causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of cardiovascular-related hospitalization</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of times that a subject is hospitalized for cardiovascular-related causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>From Baseline to Month 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The total number of deaths in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR stabilization at Month 1</measure>
    <time_frame>From Baseline to Month 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tafamidis stabilizes the transthyretin (TTR) tetramer by binding with very high affinity to the two thyroxine binding sites, preventing the tetramer from dissociating along the weak dimer-dimer interface.  TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis, expressed as a percentage change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Transthyretin (TTR) Amyloid Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Tafamidis - 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tafamidis - 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>Tafamidis 20 mg in soft gel capsules administered once a day for 30 months</description>
    <arm_group_label>Tafamidis - 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>Tafamidis 80 mg in soft gel capsules administered once a day for 30 months</description>
    <arm_group_label>Tafamidis - 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in soft gel capsules administered once a day for 30 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or
             clinical evidence of HF (without hospitalization) manifested by signs or symptoms of
             volume overload or elevated intracardiac pressures (e.g., elevated jugular venous
             pressure, shortness of breath or signs of pulmonary congestion on x-ray or
             auscultation, peripheral edema) that required/requires treatment with a diuretic for
             improvement,

          -  Evidence of cardiac involvement by echocardiography with an end-diastolic
             interventricular septal wall thickness &gt; 12 mm,

          -  Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype
             and/or TTR precursor protein identification by mass spectrometry.

        Exclusion Criteria:

          -  A New York Heart Association (NYHA) classification of IV.

          -  Presence of primary (light chain) or secondary (SAA) amyloidosis.

          -  Prior liver or heart transplantation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461028&amp;StudyName=Safety%20and%20Efficacy%20of%20Tafamidis%20in%20Patients%20with%20Transthyretin%20Cardiomyopathy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyloidosis</keyword>
  <keyword>amyloid</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
